Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France

Laure-Amélie de Monteynard1, Sophie Matheron2,3, Sophie Grabar1,4,5, Pierre de Truchis6, Jacques Gilquin7, Juliette Pavie6, Odile Launay9,10, Jean-Luc Meynard11, Marie-Aude Khuong-Josses12, David Rey13, Aba Mahamat14, Rosemarie Dray-Spira1, Anne Simon15, Dominique Costagliola1, Sophie Abgrall1,16, on behalf of the FHDH-ANRS CO4

1 Sorbonne Universités, UPMC Université Paris 06, INSERM, Institut Pierre Louis d’épidémiologie et de Santé Publique (IPELS UMR 1136), Paris, France, 2 Sorbonne Paris cité, Université Paris Diderot, UMR 1137, Paris, France, 3 AP-HP, Hôpital Bichat-Claude Bernard, Service des Maladies Infectieuses et Tropicales, Paris, France, 4 Université Paris Descartes, Sorbonne Paris cité, Paris, France, 5 APHP, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Unité de Biostatistique et Épidémiologie, Paris, France, 6 AP-HP, Hôpitaux Universitaires Paris-Ile de France-Ouest, Hôpital Raymond-Poincaré, Département de Médecine Aigüe Spécialisée, Garches, France, 7 AP-HP, Hôpital Hôtel-Dieu, Unité d’immunopathologie, Paris, France, 8 AP-HP, Hôpitaux Universitaires Paris-Ile de France-Ouest, Hôpital Européen Georges Pompidou, Service d’immunologie clinique, Paris, France, 9 Université Paris Descartes, Sorbonne Paris cité, Paris, France, 10 AP-HP, Hôpital Cochin, Paris, France, 11 AP-HP, Hôpital Saint Antoine, Service des Maladies Infectieuses et Tropicales, Paris, France, 12 Centre Hospitalier Saint-Denis, Hôpital Delafontaine, Service des Maladies Infectieuses et Tropicales, Saint-Denis, France, 13 Hôpitaux Universitaires Strasbourg, Centre de Soins de l’Infection par le VIH, Strasbourg, France, 14 Centre Hospitalier André Rosemon, Service des Maladies Infectieuses et Tropicales, Cayenne, France, 15 AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de médecine interne, Paris, France, 16 AP-HP, Hôpital Antoine Béclère, Service de Médecine interne/Immunologie clinique, Clamart, France

Current address: Université Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP INSERM U1018, Le Kremlin-Bicêtre, France.

The full list of FHDH-ANRS-CO4 can be found in the Acknowledgments section.

* sophie.abgrall@aphp.fr

Abstract

Background

The influence of geographic origin on the risk of severe illness and death on cART has not been explored in European countries.

Method

We studied antiretroviral-naïve heterosexual HIV-1-infected individuals enrolled in the FHDH-ANRS CO4 cohort in France who started cART between 2006 and 2011. Individuals originating from France (French natives), sub-Saharan Africa (SSA) and non-French West-Indies (NFW) were studied until 2012. Crude and adjusted rate ratios (aRR) of severe morbidity events/deaths (AIDS-related and non-AIDS-related) were calculated using Poisson regression models stratified by sex, comparing each group of migrants to French natives.
Results

Among 2334 eligible men, 1379 (59.1%) originated from France, 838 (35.9%) from SSA and 117 (5.0%) from NFW. SSA male migrants had a higher aRR for non-AIDS infections, particularly bacterial infections (aRR 1.56 (95% CI 1.07–2.29), p = 0.0477), than French natives. Among 2596 eligible women, 1347 (51.9%) originated from France, 1131 (43.6%) from SSA, and 118 (4.5%) from NFW. SSA and NFW female migrants had a higher aRR for non-AIDS infections, particularly non-bacterial infections (respectively, 2.04 (1.18–3.53) and 7.87 (2.54–24.4), p = 0.0010), than French natives. We observed no other significant differences related to geographic origin as concerns the aRRs for AIDS-related infections or malignancies, or for other non-AIDS events/deaths such as cardiovascular disease, neurological/psychiatric disorders, non-AIDS malignancies and iatrogenic disorders, in either gender.

Conclusion

Heterosexual migrants from SSA or NFW living in France have a higher risk of non-AIDS-defining infections than their French native counterparts. Special efforts are needed to prevent infectious diseases among HIV-infected migrants.

Introduction

In high-income countries, HIV-infected adults with controlled infection and high CD4 cell counts currently live longer than ever before [1], and the main causes of morbidity and mortality have switched from AIDS-defining to non-AIDS-defining disorders [2,3,4,5,6,7,8,9]. In western European countries, despite experiencing more AIDS-defining events [10,11], migrants from sub-Saharan Africa (SSA) have lower mortality than non-migrants, mainly owing to lower non-AIDS mortality [12]. In France, heterosexual migrant men originating from SSA and non-French West Indies (NFW), and non-migrant men, have a higher risk of new AIDS-defining events, serious non-AIDS events or death after cART initiation than non-migrant men who have sex with men (MSM), while this is not the case of women [9]. This latter study compared heterosexual individuals to MSM, two groups with different socioeconomic and lifestyle factors, and specific causes of morbidity were not assessed. In addition, no previous study has examined the specific morbidity of migrants compared to non-migrants. We therefore described and compared causes of severe morbidity and mortality between SSA or NFW migrant and non-migrant heterosexual HIV-infected men and women between 2006 and 2012.

Methods

Individuals

Created in 1989, the French Hospital Database on HIV (FHDH, ANRS CO4) is a large prospective cohort of HIV-infected individuals receiving care in one of 70 French participating hospitals, collecting standardized clinical, therapeutic and biological variables at each outpatient visit or hospital admission and/or at least every 6 months [13]. The only enrolment criteria are documented HIV-1 or HIV-2 infection, follow-up in a FHDH participating centre, and written informed consent. Data submitted by the participating centres to the data coordinating and analysis centre are anonymized, then encrypted. The FHDH was approved by the French data
protection agency (Commission Nationale de l’Informatique et des Libertés) on 27 November 1991 (Journal Officiel, 17 January 1992). For the present study, we selected antiretroviral-naive heterosexual HIV-1-infected individuals from the FHDH, aged at least 16 years, who started a first combined antiretroviral therapy (cART) between 1 January 2006 and 31 December 2011, at least one year prior to the database update (31 December 2012). Individuals were excluded if their first cART regimen was prescribed for pregnancy. Patients had to have at least one CD4 cell count and one plasma viral load (pVL) measurements within 6 months prior to treatment initiation and one CD4 cell count and one pVL measurements following cART initiation. Migrant status was based on the United Nations definition, as follows: “anyone born and having lived outside France and now residing in France, whatever their nationality and the duration of stay in France” [14]. All individuals originating from France, including the French West Indies (Martinique, Guadeloupe, French Guyana), SSA or NFW, were considered.

Coding causes of severe events

Severe events included any AIDS-defining event or death from AIDS [15] and any serious non-AIDS event or death from causes other than AIDS occurring between cART initiation and 31 December 2012. A serious non-AIDS event was defined as the primary underlying cause of any unscheduled hospitalization for more than 24 hours when an AIDS event was not the reason for hospitalization. If more than one non-AIDS event was notified for one hospitalization with no main reason notified in the discharge file, the most severe event was chosen as the cause for hospitalization in a hierarchical way: non-AIDS cancer, cardiovascular event, end-stage renal failure, acute liver failure, suicide attempt, infection, iatrogenic systemic event, then other systemic event. Hospitalization for a non-morbid cause (routine check-up, chemotherapy, blood transfusion, etc.) was not considered. If any of the following severe morbid events for which hospitalization is essential was reported outside the context of an hospitalization, ie non-AIDS-defining cancer, cardiovascular event (stroke, myocardial infarction or coronary revascularization), deep-vein thrombosis or pulmonary embolism, end-stage renal disease (dialysis or renal transplantation), decompensated liver disease, complicated diabetes mellitus, severe bacterial, fungal, viral or parasitic infection, acute neuropsychiatric diseases (e.g. suicide attempt), acute surgical conditions (e.g. gastrointestinal bleeding), it also counted as a serious non-AIDS event as proposed elsewhere [8,16]. All successive events were considered for each patient.

Severe events were categorized according to the Coding of Death in HIV (CoDe) (available at: http://www.cphiv.dk/Portals/0/files/Code%20Protocol%202.3.pdf), adapted to take AIDS and severe non-AIDS events into account, in addition to death. We grouped causes as follows: AIDS-defining infection (CoDe 01.1), AIDS-defining malignancy (CoDe 01.2), non-AIDS bacterial infection (CoDe 02.1), other non-AIDS infection (CoDe 02.2), liver-related disorder (CoDe 03 and 14), non-AIDS malignancy (CoDe 04), respiratory disease (CoDe 13 and 25), renal failure and urogenital disease (CoDe 15 and 28), central neurological and psychiatric disorders (CoDe 19, 22 and 23), gastrointestinal disorders (CoDe 10 and 26), skin, rheumatic and peripheral neurological disorders (CoDe 27), haematological disease (CoDe 20), accidental/violent events (CoDe 16 and 17) and endocrine and metabolic disease (CoDe 05, 06 and 21), as proposed elsewhere [2]. In addition, owing to the large number of events, a category of “iatrogenic disorders” was created including any reported event, mainly cutaneous, hematological, hepatic or intestinal, associated with drug toxicity. Other causes not mentioned in this classification, and unknown causes, were classified as “other”. Only categories with more than 20 events/deaths are presented here.
Statistical analysis

The Chi2 and Kruskal-Wallis tests were used to compare the demographic, immunovirological and clinical characteristics of the individuals at cART initiation, across the three regions of origin, in men and in women. The number of severe events, person-years at risk, and incidence rates (IRs) of severe events (per 1000 person-years of follow-up) were calculated. Person-years of follow-up were calculated from the date of cART initiation to the date of death for known deceased individuals, last follow-up visit for individuals with no follow-up visit during the 6-month period before 31 December 2012 (last database update) or 31 December 2012 for the remainder of the cohort. Crude and adjusted IRs were estimated according to geographic origin, in men and in women. Poisson regression models were used to identify differences in morbidity/mortality according to geographic origin, in men and in women. Incidence rates (IRs) and rate ratios (RRs) were adjusted for the following characteristics at cART initiation: age, region of care (Paris area, other regions of metropolitan France plus the Reunion Island and French West Indies), CD4 cell count, pVL, AIDS status, hepatitis B and/or C infection and smoking status for each category of events/deaths, plus the body mass index for cardiovascular diseases. All analyses were done with SAS v9.4 software (SAS Institute, Inc, Cary, NC). A p value <0.05 was considered to denote statistical significance.

Results

Population

A total of 2334 men and 2596 women fulfilled the inclusion criteria for this study. The men’s geographic origin was France in 1379 cases (59.1%), SSA in 838 (35.9%) and NFW in 117 (5.0%). The women’s geographic origin was France in 1347 cases (51.9%), SSA in 1131 (43.6%) and NFW in 118 (4.5%) (Table 1). In each sex, SSA migrants were the youngest individuals and NFW migrants were the oldest. At cART initiation, in men and in women, NFW migrants had the lowest CD4 cell counts and the highest rate of AIDS, while individuals originating from France had the highest CD4 cell counts and the lowest rate of AIDS. Smoking was less prevalent among migrants than among French natives, in both genders.

Incidences and risks of severe events in men

During 6524 person-years of follow-up, a total of 771 severe events, including 27 deaths, were recorded in 495 men, of whom 299 were French natives, 167 SSA migrants and 29 NFW migrants. Overall, crude IRs of severe events were 118.7 per 1000 person-years for French natives, 116.4 for SSA migrants and 125.8 for NFW migrants. Adjusted IR of severe events was highest among SSA migrants (183.6 in French natives, 226.4 in SSA migrants and 163.1 in NFW migrants), with an adjusted rate ratio (aRR) of severe events among SSA migrants estimated as 1.23 (95% confidence interval (CI): 1.04–1.47) compared to French natives. When AIDS events and severe non-AIDS events were considered separately, SSA migrants had a higher aRR of both AIDS events (1.38 (95%CI: 0.96–1.99)) and non-AIDS events (1.19 (95% CI: 0.98–1.44)) than French natives. Within the different non-AIDS events categories, there was a higher aRR of non-AIDS infections among SSA migrants (1.58 (95%CI: 1.15–2.15)) than among French natives, due to a higher aRR of non-AIDS bacterial infections in SSA migrants than in French natives (Table 2). The main non-AIDS bacterial infection was acute pneumonia, with 61 cases (40.9%). No other significant differences were observed in the aRRs of cardiovascular diseases, neurological/psychiatric disorders, non-AIDS malignancies or iatrogenic effects according to geographic origin.
Incidences and risks of severe events in women

During a follow-up of 7324 person-years, a total of 624 severe events, including 48 deaths, were recorded in 413 women, of whom 213 were French natives, 181 SSA migrants and 18 NFW migrants. Overall, crude IRs of severe events were 87.0 per 1000 person-years among French natives, 82.2 among SSA migrants and 96.3 among NFW migrants. Within the different non-AIDS events categories, there was a higher aRR of non-AIDS infections among SSA

Table 1. Characteristics of the population at cART initiation according to geographic origin in heterosexual men and women (France, 2006–2011, n = 4930).

|                        | Heterosexual men (n = 2334) | Heterosexual women (n = 2596) |
|------------------------|-----------------------------|-------------------------------|
|                        | France                 | SSA              | NFW             | France                 | SSA              | NFW             |
|                        | N = 1379               | N = 838          | N = 117         | N = 1347               | N = 1131         | N = 118         |
| Age [years, median (IQR)] | 43.7 (36.2–51.6)  | 40.3 (34.5–47.1) | 45.4 (37.9–52.0) | 38.6 (31.1–47.7)  | 34.3 (29.4–40.3) | 42.1 (34.4–49.1) |
| Period of cART initiation [n (%)] |                       |                  |                  | <0.0001               |                  |                  |
| 2006–2007              | 553 (40.1)             | 338 (40.3)       | 77 (65.8)        | 511 (37.9)             | 465 (41.1)       | 73 (61.9) |
| 2008–2011              | 826 (59.9)             | 500 (59.7)       | 40 (34.2)        | 836 (62.1)             | 666 (58.9)       | 45 (38.1) |
| Region of care [n (%)] |                          |                  |                  | <0.0001               |                  |                  |
| Paris area             | 584 (42.4)             | 650 (77.6)       | 45 (38.4)        | 660 (49.0)             | 826 (73.0)       | 45 (38.1) |
| Southeast France       | 162 (11.7)             | 27 (3.2)         | 0 (0)            | 166 (12.3)             | 32 (2.8)         | 0 (0) |
| Other/Reunion island   | 509 (36.9)             | 161 (19.2)       | 3 (2.6)          | 448 (33.3)             | 269 (23.8)       | 1 (0.9) |
| French West Indies     | 124 (9.0)              | 0 (0)            | 69 (59.0)        | 73 (5.4)               | 4 (0.4)          | 72 (61.0) |
| CD4 cell count [n (%)] | 200                    | 348 (41.5)       | 55 (47.0)        | 412 (30.6)             | 399 (35.3)       | 47 (39.8) |
| >200                   | 523 (37.9)             | 313 (39.5)       | 43 (36.7)        | 578 (42.9)             | 488 (43.2)       | 53 (44.9) |
| >350–499               | 222 (16.1)             | 121 (14.4)       | 11 (9.4)         | 251 (18.6)             | 178 (15.7)       | 12 (10.2) |
| CD4 cell count [median (IQR)] | 4.88 (4.30–5.35) | 4.84 (4.26–5.34) | 4.92 (4.30–5.39) | 0.7363               | 4.57 (3.88–5.10) | 4.58 (3.91–5.11) |
| pVL [log10 copies/mL, median (IQR)] | 20.4                    | 175 (20.9)       | 14 (12.0)        | 221 (16.4)             | 69 (6.1)         | 8 (6.8) |
| AIDS status [n (%)]    | 230 (16.7)             | 164 (19.6)       | 34 (33.3)        | 0.0001               | 166 (12.3)       | 171 (15.1) |
| Hepatitis B antigen [n (%)] | 53 (3.8)               | 80 (10.6)        | 4 (3.4)          | 0.0001               | 34 (2.5)         | 75 (6.6) |
| Hepatitis C antibodies [n (%)] | 36 (2.6)               | 20 (2.4)         | 3 (2.6)          | 0.9480               | 48 (3.6)         | 38 (3.4) |
| Smoking status [n (%)] | Never                  | 281 (20.4)       | 375 (44.7)       | 63 (53.8)             | 337 (25.0)       | 701 (62.0) |
| Previous               | 151 (10.9)             | 75 (9.0)         | 7 (6.0)          | 56 (4.2)              | 27 (2.4)         | 3 (2.5) |
| Current                | 411 (29.8)             | 175 (20.9)       | 14 (12.0)        | 221 (16.4)             | 69 (6.1)         | 8 (6.8) |
| Unknown                | 536 (38.9)             | 213 (25.4)       | 33 (28.2)        | <0.0001               | 733 (54.4)       | 334 (29.5) |
| Body mass index [n (%)] | <18                    | 11 (0.8)         | 15 (1.8)         | 0 (0)                 | 49 (6.6)         | 19 (1.7) |
| >18–30                 | 1024 (74.3)            | 653 (77.9)       | 59 (50.4)        | 911 (67.6)            | 835 (73.8)       | 51 (43.2) |
| >30                    | 69 (5.0)               | 70 (8.4)         | 4 (3.4)          | 140 (10.4)            | 120 (10.6)       | 4 (3.4) |
| Unknown                | 275 (19.9)             | 100 (11.9)       | 54 (46.2)        | <0.0001               | 247 (18.3)       | 157 (13.9) |
| Follow-up time after cART initiation [years, median (IQR)] | 2.6 (1.4–4.0) | 2.6 (1.4–4.1) | 2.3 (1.9–3.6) | 0.1636 | 2.6 (1.5–4.0) | 2.7 (1.6–4.1) |

Data are counts (proportions) and median (interquartile range)

*Including French West Indies (Martinique, Guadeloupe, French Guyana)

The Chi2 and Kruskal-Wallis tests were used to compare the demographic, immunovirological and clinical characteristics of the individuals

Abbreviations: SSA, Sub-Saharan Africa; NFW, Non-French West-Indies; cART, combination antiretroviral treatment

https://doi.org/10.1371/journal.pone.0205385.t001
Table 2. Crude and adjusted incidence rates (IRs) per 1000 person-years (PY) and 95% confidence intervals (95% CI), and crude and adjusted rate ratios (RRs) and 95% CI of clinical events/deaths by geographic origin, in heterosexual men and women (Poisson regression, n = 4930, France, 2006–2012).

| Clinical events | Geographic origin | People | Events | IRs per 1000 PY | Adjusted\(^a\) IRs per 1000 PY | RRs (95%CI) | People | Events | Adjusted\(^a\) IRs per 1000 PY | RRs (95%CI) |
|-----------------|-------------------|--------|--------|----------------|-----------------------------|-------------|--------|--------|-----------------------------|-------------|
| AIDS infections | France            | 71     | 87     | 22.4          | 26.3                        | 1           | 43     | 51     | 13.6                        | 10.3        |
|                 | SSA               | 49     | 54     | 22.9          | 34.0                        | 1.02 (0.73–1.43) | 1.29 (0.86–1.94) | 47     | 55     | 16.7                        | 11.8        |
|                 | NFW               | 8      | 11     | 37.4          | 23.6                        | 1.67 (0.89–3.12) | 0.90 (0.44–1.82) | 5      | 5      | 18.5                        | 20.4        |
|                 |                   |        |        |               |                             |              |        |        |                             |              |
|                 |                   |        |        | 0.3246        | 0.4168                      |              |        |        | 0.5180                      | 0.4450      |
| AIDS            |                   |        |        |               |                             |              |        |        |                             |              |
| malignancies    | SSA               | 14     | 14     | 5.9           | 9.5                         | 1.21 (0.61–2.42) | 1.78 (0.79–4.01) | 11     | 11     | 3.3                         | 8.0         |
|                 | NFW               | 1      | 1      | 3.4           | 3.0                         | 0.69 (0.09–5.18) | 0.56 (0.06–4.98) | 0      | 0      | -                           | -           |
|                 |                   |        |        |               |                             |              |        |        |                             |              |
|                 |                   |        |        | 0.7724        | 0.2896                      |              |        |        | 0.3051                      | 0.1291      |
| Non-AIDS        |                   |        |        |               |                             |              |        |        |                             |              |
| bacterial       | SSA               | 53     | 62     | 26.3          | 45.4                        | 1.33 (0.95–1.85) | 1.56 (1.07–2.29) | 36     | 41     | 12.4                        | 34.5        |
|                 | NFW               | 10     | 10     | 34.0          | 49.5                        | 1.71 (0.89–3.31) | 1.70 (0.82–3.56) | 6      | 6      | 22.2                        | 50.6        |
|                 |                   |        |        |               |                             |              |        |        |                             |              |
|                 |                   |        |        | 0.1253        | 0.0477                      |              |        |        | 0.3102                      | 0.6502      |
| infections      |                   |        |        |               |                             |              |        |        |                             |              |
| Non-AIDS        |                   |        |        |               |                             |              |        |        |                             |              |
| Cardiovascular  |                   |        |        |               |                             |              |        |        |                             |              |
| diseases        | SSA               | 19     | 20     | 8.5           | 7.9                         | 0.78 (0.46–1.33) | 1.08 (0.59–1.95) | 10     | 10     | 3.0                         | 5.8         |
|                 | NFW               | 3      | 3      | 10.2          | 11.4                        | 0.94 (0.29–3.04) | 1.56 (0.44–5.55) | 0      | 0      | -                           | -           |
|                 |                   |        |        |               |                             |              |        |        |                             |              |
|                 |                   |        |        | 0.6068        | 0.8016                      |              |        |        | 0.0121                      | 0.0240      |
| Central         |                   |        |        |               |                             |              |        |        |                             |              |
| neurological and psychiatric disorders |                   |        |        |               |                             |              |        |        |                             |              |
| Non-AIDS        |                   |        |        |               |                             |              |        |        |                             |              |
| malignancies    | SSA               | 8      | 8      | 0.4           | 0.6                         | 0.24 (0.03–1.91) | 0.40 (0.04–3.60) | 17     | 19     | 1.8                         | 3.6         |
|                 | NFW               | 2      | 2      | 3.4           | 4.6                         | 1.88 (0.23–15.30) | 3.30 (0.23–47.90) | 4      | 4      | 7.4                         | 8.8         |
|                 |                   |        |        |               |                             |              |        |        |                             |              |
|                 |                   |        |        | 0.1997        | 0.4395                      |              |        |        | 0.1006                      | 0.3042      |
| Iatrogenic effects |                   |        |        |               |                             |              |        |        |                             |              |
| Non-AIDS        |                   |        |        |               |                             |              |        |        |                             |              |
| malignancies    | SSA               | 9      | 12     | 5.1           | 8.8                         | 0.55 (0.29–1.05) | 0.80 (0.38–1.67) | 9      | 9      | 2.7                         | 5.9         |
|                 | NFW               | 1      | 2      | 6.8           | 7.3                         | 0.73 (0.18–3.04) | 0.70 (0.15–3.11) | 0      | 0      | -                           | -           |
|                 |                   |        |        |               |                             |              |        |        |                             |              |
|                 |                   |        |        | 0.1669        | 0.7589                      |              |        |        | 0.0208                      | 0.1932      |

Abbreviations: SSA, Sub-Saharan Africa; NFW, Non-French West-Indies; cART, combination antiretroviral therapy

\(^a\)Adjusted for variables at cART initiation: age, the region of care, the CD4 cell count, the pVL, pre-existing AIDS status, hepatitis B virus antigen and/or anti-hepatitis C virus antibody status, and the smoking status for all analyses, plus the body mass index for cardiovascular diseases

https://doi.org/10.1371/journal.pone.0205385.t002
and NFW migrants (respectively 1.40 (95%CI: 0.99–1.97) and 2.91 (95%CI: 1.36–6.22)) than among French natives, due to a higher aRR of non-AIDS non-bacterial infections (Table 2). The main non-AIDS bacterial infection was acute pneumonia, with 29 cases (27.4%), and the main non-AIDS non-bacterial infections were non-bacterial diarrhea (11 cases, 15.7%), viral meningo-encephalitis (10 cases, 14.3%), herpes zoster (9 cases, 12.8%) and malaria (6 cases, 8.6%). No other significant differences were observed in the aRR of cardiovascular diseases, neurological/psychiatric disorders, non-AIDS malignancies, or iatrogenic disorders according to geographic origin, although SSA migrants had lower crude RRs for cardiovascular and for non-AIDS malignancies events/deaths than French native women.

Discussion

We found that the likelihood of non-AIDS infections, and particularly bacterial infections, was significantly higher among male migrant from sub-Saharan Africa than among male French natives. The likelihood of non-AIDS infections, particularly non-bacterial infections, was significantly higher among female migrants from sub-Saharan Africa and non-French West Indies than among female French natives.

A recent collaborative cohort study comparing mortality in Western Europe according to geographic origin, sex and HIV transmission category [17] showed that, compared to native heterosexual men, mortality was lower among male heterosexual SSA migrants and similar among male heterosexual Caribbean migrants, whereas, compared to female heterosexual natives, mortality among female heterosexual SSA migrants was similar and mortality among female heterosexual Caribbean migrants was higher. Differences among host countries were not analyzed, despite differences in recruitment to this study, as well as differences in social determinants [18], including access to HIV screening, health care and antiretroviral therapy [19,20]. In addition, for a given country of origin, social determinants and access to medical services might have been influenced by the migrants’ native language(s) [20,21]. Non-AIDS morbidity has not previously been studied according to geographic origin.

Non-AIDS-defining events, and especially bacterial infections, now represent the leading cause of severe morbidity among HIV-infected patients [22,23,24]. Immunosuppression, even when moderate, is associated with an increased risk of bacterial, viral, fungal and parasitic infections [7,25,26]. We found that the risk of infection among heterosexual migrants from SSA or NFW was higher than among their native French counterparts. We could not explore the reasons for this difference, but one explanation might be exposure to infectious pathogens during visits to the country of origin as migrants travel more to the tropics than non migrants in Western Europe [27]. This implies a need for tailored counseling to ensure that migrants travel with enough and adequate medications, including antiretroviral drugs and antimalarial prophylaxis [28,29,30] and that they also have adequate pneumococcal and influenza vaccination, as recommended [31]. Moreover, in addition to lower CD4 cell counts at cART initiation [32], SSA and NWF migrants tends to have lower CD4 cell recovery during the first two years of treatment [9] and might thus be more vulnerable to non-AIDS infections during this period [33].

This study has several limitations. First, no data on treatment adherence are available in the FHDH database. However, we recently showed that in women and in non homosexual men followed in France, SSA and NFW migrants had no difference in time to viral undetectability than their native French counterparts [9]. Moreover, we used an intent-to-continue-treatment approach, meaning that cART interruption, which might have differed among the groups, was not taken into account in the models. However, it is noteworthy that the median number of visits per year and the median time between visits did not differ according to geographic origin or sex (data not shown). Because FHDH is implemented in infectious diseases and internal
medicine departments, non-AIDS non-infectious events leading to hospitalization in other departments may have been under-reported, leading to an underestimation of non-AIDS events. Similarly, because a predefined hierarchy was sometimes used to classify morbidity and mortality, misclassification was possible. However, there is no reason to suspect that under-reporting of some non-AIDS events or misclassification between the different clinical categories would have differed according to geographic origin. The main strength of this study is its large size and lengthy follow-up, which allowed us to assess meaningful clinical outcomes, including serious non-AIDS events in the different subgroups.

In summary, after cART initiation, heterosexual men and women from sub-Saharan Africa and non-French West Indies have a higher risk of non-AIDS infections than their native France counterparts. However, we found no other substantial differences in terms of severe AIDS or non-AIDS events/deaths in either gender. Special attention should thus be paid to the prevention of infectious diseases among migrants, including screening of vaccination status and completion of vaccine schedules [34], pre-travel counseling to prevent gastro-intestinal diseases and to prevent malaria with exposure prophylaxis counseling and chemoprophylaxis prescription, and post-travel close monitoring of infectious tropical diseases which could unbalance their care.

Acknowledgments

Clinical Epidemiology Group of the FHDH-ANRS CO4:
Scientific committee; S Abgrall, L Bernard, E Billaud, F Boué, L Boyer, A Cabié, F Caby, A Canestri, D Costagliola, L Cotte, P De Truchis, X Duval, C Duvivier, P Enel, H Fischer, J Gasnault, C Gaud, S Grabar, MA Khuong, O Launay, L Marchand, M Mary-Krause, S Matheron, G Melica-Grégoire, H Melliez, JL Meynard, M Nacher, J Pavie, L Piroth, I Poizot-Martin, C Pradier, J Reynes, E Rouveix, A Simon, L Slama, P Tattevin, H Tissot-Dupont.
COREVIH coordinating center: French Ministry of Health (G Astier, J Biga, T Kurth), Technical Hospitalization Information Agency, ATIH (N Jacquet).

Statistical analysis center: UMRS 1136 INSERM et UPMC (D Costagliola, Principal investigator, S Abgrall, S Grabar, M Guiuguet, S Lang, L Lièvre, M Mary-Krause, H Selinger-Leneman), INSERM-Transfert (V Potard).

COREVIH: Paris area: Corevih Ile de France Centre (GH Pitié-Salpêtrière: O Benveniste, A Simon, G Breton, C Lupin, E Bourzam; Hôpital Saint-Antoine: PM Girard, L Fouquernie, N Valin, B Lefebvre, M Sebire; Hôpital Tenon: G Pialoux, MG Lebrette, P Thibaut, A Adda, M Hamidi, J Cadranel, A Lavolé, A Parrot), Corevih Ile de France Est (Hôpital Saint-Louis: E Okshenhdler, L Gerard, JM Molina, W Rozenbaum, B Denis, N De Castro, C Lascoux; GH Lariboisière-Fernand Widal: JF Bergmann, V Delcey, A Lopes, P Sellier, M Parrinello; Hôpital Avicenne: O Bouchaud, N Vignon, F Méchaï, S Makhloufi, P Honoré; Hôpital Jean Verdier), Corevih Ile de France Nord (Hôpital Bichat-Claude Bernard: Y Yazdanpanah, S Matheron, S Lariven, V Joly, C Rioux; Hôpital Delafontaine: MA Khuong-Josses, M Poupard, B Taverner), Corevih Ile de France Ouest (Hôpital Ambroise Paré: E Roveix, S Greffe, C Dupont, A Freire Maresca, E Reimann; Hôpital Louis Mourier: M Bloch, F Meier, E Mortier, F Zeng, B Montoya; Hôpital Raymond Poincaré: C Perronne, P de Truchis, D Mathez, D Marigot-Outtandy, H Berthé; CH André Mignot—Le Chesnay: A Greder Belan, A Therby, C Godin Collet, S Marque Juillet, M Ruquet, S Roussin-Bretagne, P Colardelle; Hôpital Foch—Suresnes: JE Kahn, D Zucman, C Majerholc, E Fourn, D Bornarel; Hôpital Victor Dupouy—Argenteuil: I Sutton, V Masse, P Genet, B Wifag, J Gerbe; Hôpital Max Fourastier—Nanterre: V Danieluzzi, J Gerbe; CH de Meulan les Mureaux: T Akpan, M Marcou; CH F Quesnay—Mantes La Jolie: F Granier, JJ Laurichesse, V Perronne; CH de Poissy: C Veyssié-Belot, H Masson; CHI de St-
Germain-en-Laye: Y Welker, P Brazille), Corevih Ile de France Sud (Hôpital Européen Georges Pompidou: L Weiss, J Pavie, MI Lucas, C Jung, M Ptak; GH Tarnier-Cochin: D Salmon, C Le Jeunne, O Launay, P Guet, MP Pietri, E Pannier Metzger, V Marcou, P Loulergue, N Dupin, JP Morini, J Deleuze, P Gerhardt, J Chanal; Hôtel Dieu: JP Viard, J Ghosn, P Gazelet, A Cros, A Maignan; Hôpital Antoine Béclère: F Boué, S Abgrall, V Chambrin, I kansau, M Raho-Moussa; Hôpital de Bicêtre: D Vittecoq, O Derradj, C Bolliot, C Goujard, E Teicher, J Gasnault, M Mole, K Bourdíc; Hôpital Henri Mondor: JD Lelievre, G Melica, M Saidani, C Chesnel, C Dumont; Hôpital Necker: C Duvivier, O Lortholary, C Rouzaud, F Touam, K Benhadj; CMIP Pasteur: PH Consigny, P Bossi, A Gergely, G Cessot, F Durand).

Outside Paris area: Corevih Alsace (CHU de Strasbourg: D Rey, M Partisani, A Moulinher), Corevih Basse-Normandie (CHU de Caen: R Verdon, S Dargère, E Haustraete, P Férat, P Goubin), Corevih Bourgogne (CHU de Dijon: P Chavanet, A Fillion, L Piroth, D Croisier, S Gohier), Corevih Bretagne (CHU de Nantes: F Arvieux, F Fouala, JM Chaplains, M Ratajczak, J Rohan), Corevih Centre (CHRU de Tours), Corevih Franche-Comté (CHU de Besançon: C Chirouze, L Hustache-Mathieu, JF Faucher, A Proust, N Magy-Bertrand, H Gil, N Méaux-Ruault; CH de Belfort: JP Faller, O Ruyer, V Gendrin, L Toko), Corevih Haute-Normandie (CHU de Rouen), Corevih Languedoc-Roussillon (CHU de Montpellier; CHU de Nimes: A Sotto, I Rouanet, JM Mauboussin, R Donesco, G Jacques), Corevih Lorraine (CHU de Nancy: T May, C Rabaud, M Andre, M Delestang, MP Boullion; CH de Reims: F Bani-Sadr, C Rouger, JL Berger, Y Nguyen), Corevih Madri-Pyrénées Limousin (Toulouse CHU Purpan: B Marchou, P Delobel, G Martin Blondel, L Cuzin, N Biezunski, L Alric, D Bonnet, M Guivarch, A Palacin, V Payssan), Corevih Nord-Pas de Calais (CH de Tourcoing: H Melliez, F Ajana, A Meybeck, N Viget), Corevih PACA Est (Nice Hôpital Arcth 1: C Pradier, P Pugliese, PM Roger, E Rosenthal, J Durant, E Cua, A Naqvi, I Perbost, K Risso; CH Antibes-Juan les Pins: D Quinsat; CH de Fréjus/St Raphael: P Del Giudice; CH de Grasse: PY Dides), Corevih PACA Ouest (Marseille Hôpital de la Conception: P Enel, R Sambuc, MS Antonini-Bouvenot, P Druart, L Meddeb, I Ravaux, A Menard, C Tomei, C Dhiver, H Tissot-Dupont; Marseille Hôpital Nord: J Moreau, S Mokhtari, MJ Soavi, V Thomas; Marseille Hôpital Sainte-Marguerite: I Poizot-Mart, S Bregigeon, O Faucher, V Obry-Roguet, A Soret, N Petit; Marseille Centre pénitentiaire des Baumettes: C Bartoli, JM Ruiz, D Blanc; CH d’Aix-en-Provence: T Allegre, M Sordage, JM Riou, C Faudon; CH d’Avignon: B Plaix, H Zerarhi, E Boulat, S Chebrek, M Beyrne; CH de Digne Les Bains: P Granet Brunello; CH de Gap: L Pelissier, D Bonnel; CH de Martigues: R Cohen Valensi, B Mouchet, G Mboungou; CH de Toulon: A Lapeulisse, E F. Raff, C Allavera, E Billaud, N Hall, V Reliquet), Corevih de la Vallée du Rhône (Lyon Hôpital de la Croix-Rousse: C Chidiac, L Cotte, T Ferry, T Perpoint, P Miailhes; Lyon Hôpital Edouard Herriot: A Boibieux, JM Livrozet, D Mahloufi, F Brunel, P Chiarello).

Overseas: Corevih Guadeloupe (CHU de Pointe-à-Pitre: B Hoen, I Lamy, I Fabre, K Samar, E Duvallon; CH Saint-Martin: C Clavel, S Stegmann, W Walter), Corevih Guyane (CH de Cayenne: M Nacher, L Adirouch, F Huber, V Vantickle, P Couppié), Corevih Martinique (CHU de Fort-de-France: A Cabi, S Abel, S Pierre-François), Corevih de La Réunion (CHU Félix Guyon: C Gaud, C Ricaud, R Rodet, G Martel, A Sautron; GH Sud Réunion: P Poubeau, G Borgherini, G Camuset).
Author Contributions

Conceptualization: Laure-Amélie de Monteynard, Dominique Costagliola, Sophie Abgrall.

Data curation: Laure-Amélie de Monteynard.

Formal analysis: Laure-Amélie de Monteynard.

Funding acquisition: Dominique Costagliola.

Investigation: Sophie Matheron, Sophie Grabar, Pierre de Truchis, Jacques Gilquin, Juliette Pavie, Odile Launay, Jean-Luc Meynard, Marie-Aude Khuong-Josses, David Rey, Aba Mahamat, Anne Simon, Sophie Abgrall.

Methodology: Laure-Amélie de Monteynard, Sophie Grabar, Rosemarie Dray-Spira, Dominique Costagliola, Sophie Abgrall.

Project administration: Dominique Costagliola.

Supervision: Dominique Costagliola, Sophie Abgrall.

Validation: Sophie Matheron, Sophie Grabar, Pierre de Truchis, Jacques Gilquin, Juliette Pavie, Odile Launay, Jean-Luc Meynard, Marie-Aude Khuong-Josses, David Rey, Aba Mahamat, Rosemarie Dray-Spira, Anne Simon, Dominique Costagliola, Sophie Abgrall.

Visualization: Sophie Matheron, Sophie Grabar, Pierre de Truchis, Jacques Gilquin, Juliette Pavie, Odile Launay, Jean-Luc Meynard, Marie-Aude Khuong-Josses, David Rey, Aba Mahamat, Rosemarie Dray-Spira, Anne Simon, Sophie Abgrall.

Writing – original draft: Laure-Amélie de Monteynard, Sophie Abgrall.

Writing – review & editing: Laure-Amélie de Monteynard, Sophie Matheron, Sophie Grabar, Pierre de Truchis, Jacques Gilquin, Juliette Pavie, Odile Launay, Jean-Luc Meynard, Marie-Aude Khuong-Josses, David Rey, Aba Mahamat, Rosemarie Dray-Spira, Anne Simon, Dominique Costagliola, Sophie Abgrall.

References

1. Costagliola D, May M. Survival in individuals living with HIV. Curr Opin HIV AIDS 2016; 11:451–4. https://doi.org/10.1097/COH.0000000000000304 PMID: 27716729

2. Gill J, May M, Lewden M, Saag M, Mugavero M, Reiss P, et al. for the Antiretroviral Therapy Cohort Collaboration Study Group. Causes of Death in HIV-1-Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort Studies. Clin Infect Dis 2010; 50:1387–96. https://doi.org/10.1086/652283

3. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, et al.: EuroSIDA Study Group. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55:262–270. https://doi.org/10.1097/QAI.0b013e3181e9be6b PMID: 20700060

4. Berry SA, Fleishman JA, Moore RD, Gebo KA. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001–2008. J Acquir Immune Defic Syndr 2012; 59:368–375. https://doi.org/10.1097/QAI.0b013e318246b862 PMID: 22240460

5. Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al.; ANRS EN20 Mortalité 2010 Study Group. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS 2014; 28:1181–91. https://doi.org/10.1097/QAD.0000000000002222 PMID: 24901259

6. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Etorn Y, et al.; HPTN 052-ACTG Study Team. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014; 14:281–90. https://doi.org/10.1016/S1473-3099(13)70692-3 PMID: 24602844

7. Luz PM, Bruyand M, Ribeiro S, Bonnet F, Moreira RI, Hessamfar M, et al.; IPEC/FIOCRUZ Cohort and the Aquitaine ANRS CO3 Study Group. AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral
Severe morbidity in migrants on cART in France

therapy, France and Brazil, 2000–2008: hospital-based cohort studies. BMC Infect Dis 2014; 14:278. https://doi.org/10.1186/1471-2334-14-278 PMID: 24885790

8. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015; 373:795–807. https://doi.org/10.1056/NEJMoa1506816 PMID: 26192873

9. de Monteynard LA, Matheron S, Gilquin J, Pavie J, de Truchis P, Grabar S, et al.; FHDH-ANRS CO4. Influence of geographic origin, sex and HIV transmission group on the outcome of first-line combined antiretroviral therapy (cART) in France. AIDS 2016; 30:2235–46. https://doi.org/10.1097/QAD.0000000000001193 PMID: 27428741

10. Shepherd BS, Jenkins CA, Parrish DD, Glass TR, Cescon A, Masabeu A, et al., for the Antiretroviral Therapy Cohort Collaboration (ART-CC). Higher rates of AIDS during the first year of therapy among migrants: the importance of tuberculosis. AIDS 2013; 27:1321–9. https://doi.org/10.1097/QAD.0b013e3283faa95 PMID: 23925379

11. Monge S, Alejos B, Dronda F, Del Romero J, Iribarren JA, Pulido F, et al.; CoRIS. Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain. HIV med 2013; 14:273–83. https://doi.org/10.1111/hiv.12001 PMID: 23171059

12. Del Amo J, Jarrín I, May M, Dabis F, Crane H, Podzamczer D, et al. for the Antiretroviral Therapy Collaboration (ART-CC). Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe and the United States. Clin Infect Dis 2013; 56:1680–9. https://doi.org/10.1093/cid/cit111

13. Mary-Krause M, Grabar S, Lievre L, Abgrall S, Billaud E, Boué F, et al. Cohort Profile: French Hospital Database on HIV (FHDH-ANRS CO4). Int J Epidemiol 2014; 43:1425–36. https://doi.org/10.1093/ije/dyu002 PMID: 24550249

14. Thierry X. International migrations in Europe: towards harmonization of statistics. INED Populat Soc 2008; 442:1–4. Available at: http://www.ined.fr/en/publications/population-and-societies/harmonization-european-statistics-international-migration/ Accessed 30 january 2017.

15. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:RR-17: 1–19. PMID: 1361652

16. TEMPRANO ANRS 12136 Study Group, Daniel C, Moh R, Gabillard D, Badjé A, Le Carrou J, Ouassa T, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 2015; 373:808–22. https://doi.org/10.1056/NEJMoa1507198 PMID: 26193126

17. Monge S, Jarrín I, Mocroft A, Sabin CA, Touloumi G, van Sighem A, et al.; Migrants Working Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. Mortality in migrants living with HIV in western Europe (1997–2013): a collaborative cohort study. Lancet HIV 2015; 2:e540–9. https://doi.org/10.1016/S2352-3018(15)00203-9

18. Del Amo J, Lodi S, Dray-Spira R, Wittkop L, Monge S, Braun D, et al. The Socio-economic Inequalities and HIV Working Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in Euro-Cord. Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe. AIDS 2017; 31:253–62. https://doi.org/10.1097/QAD.0000000000001270

19. European Centre for Disease Prevention and Control (ECDC). Thematic report: migrants monitoring implementation of the dublin declaration on partnership to fight HIV/AIDS in Europe and Central Asia: 2012 progress. 2013 Available at: http://ecdc.europa.eu/en/publications/Publications/dublin-declaration-monitoring-report-migrants-september-2013.pdf Accessed 24 january 2017.

20. O’Donnell C, Burns N, Dowrick C, Lions C, MacFarlane A; RESTORE team. Health-care access for migrants in Europe. Lancet 2013; 382:393.

21. Abgrall S, Del Amo J. Effect of sociodemographic factors on survival of people living with HIV. Curr Opin HIV AIDS 2016; 11:501–06. https://doi.org/10.1097/COH.0000000000000301 PMID: 27272536

22. Ferry T, Raffi F, Collin-Filleul F, Dupon M, Dellamonica P, Waldner A, et al., ANRS CO8 (APROCO-COPILOTE) Study Group. Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO-COPILOTE (ANRS CO8) cohort study. J Acquir Immune Defic Syndr 2009; 51:407–415. https://doi.org/10.1097/QAI.0b013e3181b013e3 PMID: 19474755

23. Hессамфар M, Colin C, Bruyand M, Decoin M, Bonnet F, Mercié P, et al.; GECSA study group. Severe morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine Cohort. PLoS One 2014; 9:e102671. https://doi.org/10.1371/journal.pone.0102671 PMID: 25076050

24. Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV 2015; 2: e438–444. https://doi.org/10.1016/S2352-3018(15)00137-X PMID: 26423651
25. Collin A, Le Marec F, Vandenhende MA, Lazaro E, Duffau P, Cazanave C, et al., ANRS CO3 Aquitaine Cohort Study Group. Incidence and risk factors for severe bacterial infections in people living with HIV. ANRS CO3 Aquitaine Cohort, 2000–2012. PloS One 2016; 11:e0152970. https://doi.org/10.1371/journal.pone.0152970 PMID: 27050752

26. van Veen KEB, Brouwer MC, van der Ende A, van de Beek D. Bacterial meningitis in patients with HIV: A population-based prospective study. J Infect 2016; 72:362–368. https://doi.org/10.1016/j.jinf.2016.01.001 PMID: 26774622

27. Gebreselasie HM, Kraus D, Fux CA, Haubitz S, Scherrer A, Hatz C, et al. Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV Cohort Study. HIV Medicine 2017; 18:564–72. https://doi.org/10.1111/hiv.12491 PMID: 28247589

28. Mouala C, Houzé S, Guiguet M, Abboud P, Pialoux G, Viget N, et al. Imported Malaria in HIV-Infected Patients Enrolled in the ANRS CO4 FHDH Study. J Acquir Immune Defic Syndr 2008; 49:55–60. https://doi.org/10.1097/QAI.0b013e31817e635b PMID: 18667929

29. Abgrall S, Fugon L, Lélé N, Carde E, Bentata M, Patay O, et al. and the ANRS VIHVO Study Group. Risk factors for adherence failure in HIV-infected sub-Saharan migrants living in France and travelling back to their native country. Int J STD AIDS 2014; 25:389–90. https://doi.org/10.1177/0956462413506894 PMID: 24667876

30. Ansart S, Caumes E. Pneumopathies au retour de voyage. Rev Mal Respir 2002; 18:693–697. Available at: http://www.em-consulte.com/rmr/article/151537. Accessed 30 January 2017.

31. Yeni P et le groupe d’experts sur l’infection à VIH. Prise en charge médicale des personnes infectées par le VIH. Paris: Flammarion médecine-sciences 2008. Available at: http://www.ladocumentationfrancaise.fr/var/storage/rapports-publics/084000593.pdf Accessed 31 January 2016.

32. Montlahuc C, Guiguet M, Abgrall S, Daneluzzi V, de Salvador F, Launay O, et al.; French Hospital Database ANRS CO4 cohort. Impact of late presentation on the risk of death among HIV-infected people in France (2003–2009). J Acquir Immune Defic Syndr 2013; 64:197–203. https://doi.org/10.1097/QAI.0b013e31829cfa PMID: 24047970

33. Lapadula G, Chatenoud L, Gori A, Castelli F, Di Giambenedetto S, Fabbiani M, et al., Italian MASTER Cohort. Risk of Severe NON AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts > 200/µl Despite Effective HAART. PloS One 2015; 10(5):e0124741. https://doi.org/10.1371/journal.pone.0124741 PMID: 26020849

34. Mullerart J, Abgrall S, Lélé N, Batteux F, ben Slama L, Meritet JF, et al.; for the ANRS VIHVO Study Group. Diphtheria, Tetanus, Poliomyelitis, Yellow Fever and Hepatitis B Seroprevalence among HIV1-infected Migrants. Results from the ANRS VIHVO vaccine sub-study. Vaccine 2015; 33:4936–44. https://doi.org/10.1016/j.vaccine.2015.07.036 PMID: 26209841